Invitae Corp (NVTAQ)

[shub]

"ASCO Data Shows Prostate Cancer Patients with Genetic Risk Factors Missed Under Current Testing Guidelines
8:17 am ET June 5, 2017 (PR Newswire) Print

A new analysis of genetic testing results among prostate cancer patients shows a substantial portion of patients with clinically significant genetic variants will be missed under current testing guidelines. These data add to the evidence supporting the re-evaluation of germline genetic testing guidelines for prostate cancer patients. The study was presented by a team including researchers from Invitae Corporation (NYSE: NVTA) and the Tulane University School of Medicine at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, where it was designated a "Best of ASCO" presentation.

https://mma.prnewswire.com/media/268592/invitae_corporation_logo.jpg "

This encouraging news wins us a 5% SP drop...sigh..suck-a-duck market sentiment.